UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (12), p.1483-1492

2019

Volltextzugriff (PDF)

Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans

International journal of molecular sciences, 2023-06, Vol.24 (13), p.10471

2023

Volltextzugriff (PDF)

Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries

European journal of preventive cardiology, 2022-12, Vol.29 (17), p.2264-2271

2022

Volltextzugriff (PDF)

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

Journal of clinical lipidology, 2014, Vol.8 (1), p.94-106

2014

Volltextzugriff (PDF)

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome

Diseases, 2023-10, Vol.11 (4), p.140

2023

Volltextzugriff (PDF)

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

Archives of medical science, 2023-01, Vol.19 (4), p.995-1002

2023

Volltextzugriff (PDF)

Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia

Current atherosclerosis reports, 2020-09, Vol.22 (11), p.68-68, Article 68

2020

Volltextzugriff (PDF)

Induced pluripotent stem cell line ICGi036-A generated by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia caused due to compound heterozygous p.Ser177Leu/p.Cys352Arg mutations in LDLR

Stem cell research, 2022-03, Vol.59, p.102653-102653, Article 102653

2022

Volltextzugriff (PDF)

Induced pluripotent stem cell line ICGi037-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to heterozygous p.Trp443Arg mutations in LDLR

Stem cell research, 2022-04, Vol.60, p.102703-102703, Article 102703

2022

Volltextzugriff (PDF)

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Archives of medical science, 2017-08, Vol.13 (5), p.965-1005

2017

Volltextzugriff (PDF)

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

JAMA cardiology, 2020-06, Vol.5 (6), p.709

2020

Volltextzugriff (PDF)

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.71, Article 71

2019

Volltextzugriff (PDF)

iPSC-Derived Endothelial Cells Reveal LDLR Dysfunction and Dysregulated Gene Expression Profiles in Familial Hypercholesterolemia

International journal of molecular sciences, 2024-01, Vol.25 (2), p.689

2024

Volltextzugriff (PDF)

Induced pluripotent stem cell line ICGi038-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to compound heterozygous c.1246C > T/c.940 + 3_940 + 6del mutations in LDLR

Stem cell research, 2022-04, Vol.60, p.102702-102702, Article 102702

2022

Volltextzugriff (PDF)

Calling and Phasing of Single-Nucleotide and Structural Variants of the LDLR Gene Using Oxford Nanopore MinION

International journal of molecular sciences, 2023-02, Vol.24 (5), p.4471

2023

Volltextzugriff (PDF)

Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels

Biomolecules (Basel, Switzerland), 2019-03, Vol.9 (4), p.129

2019

Volltextzugriff (PDF)

World Heart Federation Cholesterol Roadmap 2022

Global heart, 2022-10, Vol.17 (1), p.75-75

2022

Volltextzugriff (PDF)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease

Journal of cardiovascular development and disease, 2021-01, Vol.8 (2), p.11

2021

Volltextzugriff (PDF)

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

Current atherosclerosis reports, 2019-09, Vol.21 (9), p.36-36, Article 36

2019

Volltextzugriff (PDF)

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis

Journal of cardiovascular development and disease, 2021-06, Vol.8 (6), p.63

2021

Volltextzugriff (PDF)

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis

Diseases, 2023-03, Vol.11 (1), p.43

2023

Volltextzugriff (PDF)

Lipoprotein(a) apheresis

Current opinion in lipidology, 2016-08, Vol.27 (4), p.351-358

2016

Volltextzugriff (PDF)

Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia

Atherosclerosis, 2018-10, Vol.277, p.477-482

2018

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Englisch
(118)
Russisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans

Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia

Induced pluripotent stem cell line ICGi036-A generated by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia caused due to compound heterozygous p.Ser177Leu/p.Cys352Arg mutations in LDLR

Induced pluripotent stem cell line ICGi037-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to heterozygous p.Trp443Arg mutations in LDLR

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

iPSC-Derived Endothelial Cells Reveal LDLR Dysfunction and Dysregulated Gene Expression Profiles in Familial Hypercholesterolemia

Induced pluripotent stem cell line ICGi038-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to compound heterozygous c.1246C > T/c.940 + 3_940 + 6del mutations in LDLR

Calling and Phasing of Single-Nucleotide and Structural Variants of the LDLR Gene Using Oxford Nanopore MinION

Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels

World Heart Federation Cholesterol Roadmap 2022

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis

Lipoprotein(a) apheresis

Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia

Suchergebnisse filtern